35 related articles for article (PubMed ID: 10193641)
1. Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.
Marasca R; Maffei R; Morselli M; Zucchini P; Castelli I; Martinelli S; Fontana M; Ravanetti S; Curotti M; Leonardi G; Cagossi K; Partesotti G; Torelli G
J Mol Diagn; 2005 Nov; 7(5):566-74. PubMed ID: 16258154
[TBL] [Abstract][Full Text] [Related]
2. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.
Aruga Y; Ikeda C; Matsushita H; Makita S; Fukuhara S; Munakata W; Izutsu K; Matsui H
Sci Rep; 2024 Jun; 14(1):13452. PubMed ID: 38862612
[TBL] [Abstract][Full Text] [Related]
3. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
[TBL] [Abstract][Full Text] [Related]
4. Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons.
Elter T; Eichhorst BF; Wendtner CM
Curr Hematol Malig Rep; 2009 Jan; 4(1):43-6. PubMed ID: 20425437
[TBL] [Abstract][Full Text] [Related]
5. New agents in chronic lymphocytic leukemia.
Robak T
Curr Treat Options Oncol; 2006 May; 7(3):200-12. PubMed ID: 16615876
[TBL] [Abstract][Full Text] [Related]
6. Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.
Robak T
Drugs Aging; 2005; 22(12):983-1012. PubMed ID: 16363884
[TBL] [Abstract][Full Text] [Related]
7. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia.
Peková S; Marková J; Pajer P; Dvorák M; Cetkovský P; Schwarz J
Mol Diagn; 2005; 9(1):23-34. PubMed ID: 16035732
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement.
Maloum K; Pritsch O; Dighiero G
Hematol Cell Ther; 1997 Jun; 39(3):119-24. PubMed ID: 9262987
[TBL] [Abstract][Full Text] [Related]
9. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
10. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL).
Magnac C; Sutton L; Cazin B; Laurent C; Binet JL; Merle-Béral H; Dighiero G; Maloum K
Hematol Cell Ther; 1999 Feb; 41(1):13-8. PubMed ID: 10193641
[TBL] [Abstract][Full Text] [Related]
11. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
[TBL] [Abstract][Full Text] [Related]
12. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation.
Provan D; Bartlett-Pandite L; Zwicky C; Neuberg D; Maddocks A; Corradini P; Soiffer R; Ritz J; Nadler LM; Gribben JG
Blood; 1996 Sep; 88(6):2228-35. PubMed ID: 8822943
[TBL] [Abstract][Full Text] [Related]
13. Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation.
Zwicky CS; Maddocks AB; Andersen N; Gribben JG
Blood; 1996 Nov; 88(9):3314-22. PubMed ID: 8896395
[TBL] [Abstract][Full Text] [Related]
14. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas.
Pott C; Tiemann M; Linke B; Ott MM; von Hofen M; Bolz I; Hiddemann W; Parwaresch R; Kneba M
Leukemia; 1998 Oct; 12(10):1630-7. PubMed ID: 9766510
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.
Vuillier F; Claisse JF; Vandenvelde C; Travade P; Magnac C; Chevret S; Desablens B; Binet JL; Dighiero G
Leuk Lymphoma; 1992 Jun; 7(3):195-204. PubMed ID: 1282428
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
